LL-37 UK: Complete Research Guide (2026)

Introduction: Understanding LL-37

LL-37, also known as cathelicidin antimicrobial peptide (hCAP18/LL-37), represents the sole human cathelicidin and has become a focal point for research spanning immunology, microbiology, and wound healing. This 37-amino-acid peptide is derived from the N-terminal region of the human cationic antimicrobial protein 18 (hCAP18) and plays multifaceted roles in both innate immunity and tissue repair.

Research Disclaimer: This guide is intended for educational and research purposes only. All information reflects current scientific literature and should not be construed as medical advice. LL-37 and related peptides are supplied for laboratory research only and are not approved for human therapeutic use.

What is LL-37? Molecular Structure and Origin

LL-37 is a cationic antimicrobial peptide (AMP) composed of 37 amino acids with a net positive charge at physiological pH. This structural feature is critical to its mechanism of action. The peptide is primarily produced by neutrophils, macrophages, and epithelial cells in response to infection or tissue injury. Its concentration increases significantly at sites of inflammation, wound healing, and infection, where it participates in both direct antimicrobial defence and immune signalling.

The peptide’s name derives from its terminal leucine-leucine (LL) residues and its 37-amino-acid length. Unlike many other antimicrobial peptides found in various organisms, LL-37 is the only cathelicidin expressed in humans, making it uniquely important for understanding human innate immunity.

Mechanism of Action: Dual Antimicrobial and Immunomodulatory Roles

Direct Antimicrobial Activity

LL-37 exerts its antimicrobial effects primarily through disruption of microbial membranes. The peptide’s positive charge allows it to bind to negatively charged bacterial lipopolysaccharides (LPS) and phospholipids on cell membranes. This interaction leads to:

• Membrane permeabilization and pore formation
• Disruption of membrane integrity
• Leakage of intracellular contents
• Cell lysis and death of the microorganism

This broad-spectrum mechanism is effective against gram-positive and gram-negative bacteria, as well as certain fungi and viruses.

TLR-Mediated Immunomodulation

Beyond direct antimicrobial action, LL-37 functions as an immunomodulator through interaction with toll-like receptors (TLRs), particularly TLR3 and TLR9. Through these signalling pathways, LL-37 can:

• Activate dendritic cells and enhance antigen presentation
• Promote Th1 and Th17 immune responses
• Modulate inflammatory cytokine production (IL-6, TNF-α, IL-10)
• Enhance neutrophil recruitment and activation
• Upregulate antimicrobial peptide production in epithelial cells

Antimicrobial Research: Bacterial, Viral, and Fungal Activity

Bacterial Resistance and MRSA

LL-37 demonstrates potent activity against a wide range of bacteria, including multidrug-resistant strains. Research has shown particular effectiveness against:

• Methicillin-resistant Staphylococcus aureus (MRSA): Studies indicate LL-37 can disrupt biofilm formation and kill planktonic MRSA cells, even in antibiotic-resistant strains
• Pseudomonas aeruginosa: A major nosocomial pathogen where LL-37 demonstrates bactericidal activity
• Escherichia coli: Including uropathogenic strains associated with urinary tract infections
• Mycobacterium tuberculosis: Emerging research suggests LL-37 may be relevant in TB research contexts

The resistance of bacteria to conventional antibiotics has not been observed to extend to LL-37’s membrane-disruption mechanism, suggesting potential value in antibiotic-resistant infection research.

Viral Research Applications

LL-37 shows activity against various viruses through multiple mechanisms:

• Enveloped viruses: Direct interaction with viral lipid envelopes, including influenza and coronavirus studies
• TLR9 activation: Recognition of viral DNA/RNA and triggering of innate immune responses
• Indirect antiviral effects: Enhanced interferon production and NK cell activation

Research contexts involving viral infection models increasingly incorporate LL-37 as a model antimicrobial peptide for understanding innate immune responses.

Fungal Research

LL-37 demonstrates activity against various fungi through membrane disruption mechanisms similar to bacterial targets. Research has documented effects against Candida species and other opportunistic fungi relevant in immunocompromised host models.

Wound Healing and Tissue Repair Research

One of the most extensively studied applications of LL-37 is its role in wound healing and tissue repair. Research mechanisms include:

• Angiogenesis promotion: LL-37 stimulates endothelial cell proliferation and new blood vessel formation, critical for healing
• Fibroblast activation: Enhancement of collagen deposition and extracellular matrix remodelling
• Epithelialisation: Stimulation of keratinocyte migration and proliferation at wound edges
• Infection control: Direct antimicrobial activity preventing wound infection during healing
• Growth factor signalling: Cross-talk with growth factor receptors (EGFR, TGF-β pathways)

In wound healing models, LL-37 application has been associated with improved healing kinetics, increased tensile strength, and reduced scarring in experimental studies.

Anti-Biofilm Research

Bacterial biofilms—organized communities of microorganisms encased in protective matrices—are major drivers of chronic infections. LL-37 research has shown promise in this context:

• Biofilm disruption: LL-37 can penetrate biofilm matrices and kill embedded bacteria
• Quorum sensing inhibition: Some research suggests interference with bacterial signalling pathways that maintain biofilms
• Combination potential: Studies exploring LL-37 with conventional antibiotics show enhanced biofilm disruption

This has particular relevance for chronic wound infections, cystic fibrosis-related infections, and device-associated biofilms in research models.

Inflammatory Modulation: Pro- and Anti-inflammatory Context

LL-37’s relationship with inflammation is context-dependent and remains an area of active research:

Pro-inflammatory Contexts

At low concentrations and in acute infection models, LL-37 typically promotes inflammatory responses through:

• TLR-mediated NF-κB activation
• Cytokine and chemokine induction (IL-6, IL-8, TNF-α)
• Neutrophil and macrophage recruitment

Anti-inflammatory Contexts

At higher concentrations and in chronic inflammation models, LL-37 may exert anti-inflammatory effects:

• Lipopolysaccharide (LPS) neutralization reducing endotoxin activity
• Suppression of excessive inflammatory responses
• Regulatory T cell induction in some model systems
• Downregulation of pro-inflammatory mediators in chronic settings

This dual nature underscores the complexity of LL-37 biology and the importance of concentration and context in research applications.

Cancer Research: Complex and Conflicting Findings

LL-37 has emerged as a subject of cancer research, though findings are notably heterogeneous:

Tumour-Suppressive Effects

Some research suggests LL-37 may have tumour-suppressive properties:

• Direct cytotoxic effects on certain cancer cell lines
• Induction of apoptosis through caspase activation
• Inhibition of cancer cell migration and invasion
• Enhanced anti-tumour immune responses

Pro-tumorigenic Effects

Conversely, other studies document pro-tumorigenic activities:

• Enhanced cancer cell proliferation in some contexts
• Promotion of epithelial-mesenchymal transition (EMT)
• Angiogenic effects supporting tumour vascularisation
• Immunosuppressive effects in tumour microenvironments

The divergent findings likely reflect differences in cancer type, cell line characteristics, LL-37 concentrations, and experimental conditions. This remains an area where further research is needed to clarify mechanisms and therapeutic potential.

Skin Condition Research: Rosacea, Psoriasis, and Atopic Dermatitis

LL-37 has attracted significant research attention in dermatological conditions, where dysregulation of the peptide has been implicated:

Rosacea

Elevated LL-37 levels are characteristic of rosacea pathophysiology. Research has shown:

• Excess LL-37 contributes to inappropriate inflammation and vasodilation
• Dysregulated TLR signalling amplifies LL-37 production
• LL-37 promotes mast cell degranulation contributing to flushing

Psoriasis

Elevated LL-37 is found in psoriatic plaques and appears central to pathogenesis:

• High LL-37 levels activate plasmacytoid dendritic cells via TLR9
• This triggers type I interferon responses and Th17 differentiation
• Self-DNA/LL-37 complexes perpetuate autoimmune inflammation
• Research suggests targeting LL-37 or TLR9 signalling may have therapeutic potential

Atopic Dermatitis

In atopic dermatitis (AD), LL-37 levels are paradoxically reduced, but the peptide’s role remains complex:

• Reduced LL-37 correlates with increased S. aureus colonization
• Impaired barrier function compromises LL-37 production
• Research explores restoring LL-37 function as a therapeutic strategy
• Filaggrin mutations in AD affect LL-37 processing and delivery

Delivery Challenges in LL-37 Research

LL-37 presents significant challenges for research applications, particularly regarding stability and delivery:

Rapid Degradation

LL-37 is highly susceptible to degradation by:

• Serum proteases: Rapid breakdown in blood and serum-containing media
• Tissue proteases: Matrix metalloproteinases, serine proteases, and other tissue-derived enzymes
• Bacterial proteases: Some microorganisms produce peptidases that degrade LL-37
• Time and temperature: Degradation accelerates at physiological temperature and over time

This rapid degradation complicates in vivo studies and necessitates careful protocol design to minimize peptide loss.

Delivery Strategies

Researchers employ various approaches to overcome stability limitations:

• Modified analogues: D-amino acid substitutions, cyclization, or N-terminal modifications to improve stability
• Encapsulation: Nanoparticle, liposome, or hydrogel formulations protecting peptide from proteases
• Topical application: Direct local application reducing systemic exposure and protease degradation
• Immediate use: Fresh reconstitution and rapid application protocols
• Protease inhibitor co-administration: Use of protease inhibitor cocktails to extend peptide half-life

Dosing and Concentration in Research

LL-37 dosing varies substantially across research contexts:

• In vitro studies: Typically range from 0.1 to 100 μM, with many mechanistic studies using 10-50 μM
• Cell culture: Concentrations of 1-10 μM for immunomodulation studies; higher concentrations (50+ μM) for direct antimicrobial effects
• In vivo animal models: Systemic administration: 1-10 mg/kg; topical/local application: typically 10-100 μg/wound or lesion
• Physiological concentrations: Circulating levels in healthy individuals are typically <0.5 μM, but local concentrations at infection/inflammation sites can reach 10-100 μM

Researchers must carefully calibrate doses to reflect physiologically relevant concentrations while achieving experimental endpoints.

Safety Profile and Considerations

LL-37 research has established a reasonable safety profile in experimental contexts:

• Cytotoxicity: Minimal toxicity to mammalian cells at physiologically relevant concentrations; cytotoxicity typically observed only at supraphysiological concentrations (>100 μM)
• Inflammatory effects: While pro-inflammatory at certain concentrations, LL-37 does not induce uncontrolled inflammation at therapeutic-range concentrations in most in vivo models
• Immunogenicity: As a naturally occurring human peptide, LL-37 shows minimal immunogenicity; some modified analogues may require immunogenicity assessment
• Organ toxicity: Animal studies have not revealed significant organ toxicity at research-relevant doses
• Autoimmune concerns: Given LL-37’s role in psoriasis and other autoimmune conditions, careful monitoring is warranted in susceptible individuals, though this is primarily a therapeutic consideration rather than a research safety issue

Storage and Reconstitution Guidelines

Proper handling is critical to maintain LL-37 activity:

Storage Conditions

• Powder form: Store at -20°C or -80°C in dry conditions; avoid moisture
• Optimal storage: -80°C in sealed containers with desiccant for long-term storage (12+ months)
• Short-term storage: -20°C is acceptable for periods up to 3-6 months
• Avoid freeze-thaw cycles: Multiple freeze-thaw cycles can degrade the peptide; divide into aliquots to minimize
• Light protection: Store in darkness; avoid UV exposure

Reconstitution

• Sterile water or PBS: Use sterile, nuclease-free water or phosphate-buffered saline (PBS)
• pH consideration: LL-37 is more stable at slightly acidic pH (pH 4-6) than neutral pH
• Initial concentration: Reconstitute to a stock concentration of 1-10 mg/mL, then dilute as needed
• Sterile technique: Use aseptic technique to prevent contamination
• Use promptly: Reconstituted peptide should be used within hours to days, depending on application; longer-term storage of reconstituted peptide (days to weeks) is possible at 4°C or -20°C
• Filter sterilization: For cell culture use, 0.22 μm filter sterilization is recommended

UK Legal Status and Regulatory Context

LL-37 and related peptides occupy a specific regulatory position in the UK:

• Research designation: LL-37 is available for research and laboratory use under current UK regulations
• Not approved for human use: LL-37 has no approved therapeutic application in the UK or EU
• Controlled research contexts: Academic and institutional research may proceed under appropriate ethical review and institutional oversight
• Quality and purity standards: Reputable suppliers provide certificates of analysis (COAs) confirming peptide identity and purity via HPLC and mass spectrometry
• Supply from UK sources: Several UK-based research peptide suppliers offer LL-37 with COA documentation

UK Sourcing: Finding Quality LL-37 for Research

When sourcing LL-37 for research purposes in the UK, several quality markers indicate reliable suppliers:

• Certificate of Analysis (COA): Essential documentation including HPLC purity, mass spectrometry confirmation, and endotoxin testing
• Sequence verification: Confirmation that the peptide sequence is correct (37 amino acids, starting with LL)
• Sterility and endotoxin testing: For research in cell culture and animal models
• Supplier reputation: Established UK suppliers with track records in peptide supply and demonstrated quality control
• Technical support: Availability of formulation advice, protocol support, and troubleshooting assistance
• Batch-to-batch consistency: Documentation demonstrating consistent quality across multiple batches

Frequently Asked Questions About LL-37 Research

1. What is the difference between LL-37 and other antimicrobial peptides?

LL-37 is the sole human cathelicidin, distinguishing it from defensins (also present in humans) and cathelicidins from other species. Its unique human origin makes it particularly relevant for understanding human innate immunity and translating findings to therapeutic contexts.

2. Can LL-37 be used in combination with antibiotics?

Yes, several studies have explored synergistic combinations of LL-37 with conventional antibiotics. The peptide’s distinct mechanism (membrane disruption) complements antibiotic targets, and some research shows enhanced efficacy in biofilm disruption and resistant strain treatment when used together.

3. Why does LL-37 have pro- and anti-inflammatory effects?

The concentration and context matter greatly. At low concentrations in acute infection, LL-37 promotes immune recruitment and activation. At high concentrations in chronic inflammation, it can suppress excessive inflammation and neutralize inflammatory mediators. This concentration-dependent and context-dependent behaviour is typical of many biological mediators.

4. What are the best delivery vehicles for LL-37 in vivo research?

This depends on the research question. Topical application is effective for wound and skin models. For systemic delivery, nanoparticle encapsulation (chitosan, liposomes, or polymeric nanoparticles) improves stability and bioavailability. Direct injection of freshly reconstituted peptide is common for local delivery studies.

5. How stable is LL-37 in cell culture media?

LL-37 degradation in cell culture media typically occurs over hours to days depending on serum content, temperature, and proteolytic activity of cultured cells. Serum-free media and low-temperature storage improve stability. Many researchers use fresh reconstitutions or include protease inhibitors when extended exposure is necessary.

6. Can LL-37 be modified to improve stability without losing activity?

Yes, research has documented various successful modifications including: substitution of protease-sensitive residues, cyclization, D-amino acid substitution at vulnerable positions, and N-terminal acetylation or PEGylation. The key is balancing stability gains with preservation of critical functional domains.

7. What is the relationship between LL-37 levels and infection susceptibility?

Low LL-37 levels correlate with increased infection susceptibility in some populations, particularly in genetic cathelicidin deficiency models and certain chronic skin diseases. Conversely, in autoimmune conditions like psoriasis, elevated LL-37 drives inflammation. Optimal immune function appears to require appropriately regulated LL-37 levels.

8. How do you measure LL-37 activity in research?

Multiple approaches are used: bacterial/fungal kill assays (viability staining, CFU counts), membrane permeability assays (flow cytometry, fluorescent probes), inflammatory response assays (cytokine measurement, gene expression), cell proliferation/migration assays, and in vivo efficacy models (wound healing, infection clearance). The choice depends on the research question.

9. Is LL-37 effective against antibiotic-resistant bacteria in research?

Yes, several studies have demonstrated LL-37 activity against multidrug-resistant pathogens including MRSA and resistant gram-negatives. The mechanism (membrane disruption) differs fundamentally from antibiotic mechanisms, suggesting that resistance to conventional antibiotics does not confer resistance to LL-37.

10. What are the limitations of LL-37 in cancer research?

The conflicting findings regarding tumour-suppressive vs. pro-tumorigenic effects suggest that LL-37’s role is highly context-dependent. Cancer type, cell line characteristics, LL-37 concentration, and the immune environment all influence outcomes. This complexity necessitates careful study design and interpretation of cancer-related LL-37 research.

Conclusion: LL-37 as a Research Tool

LL-37 represents a multifaceted research tool with applications spanning microbiology, immunology, wound healing, dermatology, and cancer biology. Its unique position as the sole human cathelicidin, combined with its diverse biological activities and translational relevance, makes it a valuable subject for continued research. Understanding its mechanisms, addressing delivery and stability challenges, and clarifying the context-dependent nature of its effects will be essential for maximizing its potential in both basic research and future therapeutic applications.

As research into LL-37 and related antimicrobial peptides continues to evolve, the peptide’s role in defending against infection, promoting tissue repair, and modulating immunity remains a rich area for investigation with significant implications for understanding human innate immunity.